Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Houston Methodist

Neither a doctor nor a teaching hospital

Research payments

$671,017

176 payments

Through program year 2025, Houston Methodist is reported as receiving $671,017 in research payments, across 176 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $57,464 19
2024 Research $191,598 30
2023 Research $115,716 29
2022 Research $165,171 22
2021 Research $67,389 10
2020 Research $666 3
2019 Research $73,013 63

Breakdown

Who paid Research payments · program years 2019–2025
  1. Alnylam Pharmaceuticals Inc. $207,502 75 payments
  2. Galvanize Therapeutics, Inc $124,977 11 payments
  3. Endotronix, Inc. $116,351 5 payments
  4. Ucb SA $51,455 1 payment
  5. Biohaven Pharmaceutical Holding Company Ltd. $47,598 8 payments
  6. Takeda Pharmaceuticals International, Inc. $45,513 2 payments
  7. Astellas Pharma Global Development $26,152 6 payments
  8. Becton, Dickinson and Company $23,459 3 payments
  9. Medtronic, Inc. $21,203 3 payments
  10. Pfizer Inc. $2,257 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. CS006 RheOx Pivotal $124,977 11 payments
  2. HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy $85,325 24 payments
  3. Proactive-Hf $78,187 2 payments
  4. The Healey Platform trial $51,455 1 payment
  5. Healey Platform Trial $47,598 8 payments
  6. A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) $46,370 18 payments
  7. Clinical Outcomes with Vedolizumab use Among Inflammatory Bowel Disease Patients- A Peek into the Future $45,513 2 payments
  8. HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) $42,101 17 payments
  9. Astagraf XL to Understand the Impact of Immunosuppression on de Novo Dsa Development and Chronic Immune Activation in Kidney Transplantation $26,152 6 payments
  10. Proactive-Hf $25,959 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $72,361 2 payments
  2. Other $45,513 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record